What is the latest price information for Belumosudil and has it changed?

Belumosudil mesylate tablets (Belumosudil) has recently been officially launched in the Chinese market and has been included in the national medical insurance directory, providing a new treatment option for patients with chronic graft-versus-host disease. The domestically marketed version is besudil mesylate tablets, and the common specification is 0.2g × 30 tablets. According to the latest drug bidding data and pharmaceutical company quotation information, the price of a single box is approximately more than 10,000 yuan. The specific cost may vary slightly depending on regional policies and hospital procurement channels. Compared with imported original research drugs, the domestic version may obviously be more affordable, but currently there is no domestic version available for sale in the domestic market.

In overseas markets, the price of the original drug REZUROCK in the United States is relatively high, about US$10,000 per box, and even higher in some areas. It is not generally covered by commercial insurance, posing a heavy financial burden on patients. In recent years, as the drug patent protection period approaches, generic versions of Besudil have appeared in some countries. For example, the product of the same specification produced by Lucius Pharmaceutical Factory in Laos is priced at about RMB 4,000, providing a more cost-effective alternative for patients in low- and middle-income countries.

As competition in the global market intensifies and medical insurance policies are adjusted, the price of besudil is expected to gradually decline. It is worth noting that although the ingredients of generic drugs are basically the same as the original drugs, there may be differences in the dissolution characteristics, impurity control and drug stability of different manufacturers. Therefore, it is still recommended to choose regular channels to purchase drugs under the guidance of a doctor.

Overall, besudil is becoming a representative innovative drug in the treatment of chronic graft-versus-host disease with its significant efficacy and gradually improving accessibility, and its future price trend is still worthy of attention.

Reference: https://www.drugs.com/pro/rezurock.html